Veru
€0.8865
175
+€0.04+4.23%Tuesday 20:00
Statistics
Day High
1.7242
Day Low
1.7152
52W High
4.18
52W Low
0.4038
Volume
0
Avg. Volume
9
Mkt Cap
15.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
May 2014
€0.50
Feb 2014
€0.52
Nov 2013
€0.52
Aug 2013
€0.52
May 2013
€0.53
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
Nov 26Expected
Q1 2026
Q2 2026
Next
-0.28
-0.22
-0.17
-0.11
Expected EPS
-0.22734103419999996
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-20.93MNet Income
Analyst Ratings
$19.48Average Price Target
The highest estimate is 21.25.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow FMW.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Merck
MRK
Mkt Cap368.89B
Gilead Sciences
GILD
Mkt Cap211.7B
Abbvie
ABBV
Mkt Cap521.11B
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
AMGEN
AMGN
Mkt Cap251.94B
Johnson & Johnson
JNJ
Mkt Cap657.68B
Astrazeneca
AZN
Mkt Cap289.48B
Novartis
NVS
Mkt Cap303.67B
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
About
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Show More
CEO
Mitchell S. Steiner
Employees
20
Country
United States
ISIN
US92536C1036
WKN
000A41ES4
Listings
0 Comments
Share your thoughts
FAQs
What is Veru stock price today?▼
The current price of FMW.STU is €0.89 EUR — it has increased by +4.23% in the past 24 hours. Watch Veru stock price performance more closely on the chart.
What is Veru stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Veru stocks are traded under the ticker FMW.STU.
Is Veru stock price growing?▼
FMW.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Veru has showed a +0% increase.
What is Veru market cap?▼
Today Veru has the market capitalization of 15.12M
When is the next Veru earnings date?▼
Veru is going to release the next earnings report on November 26, 2026.
What were Veru earnings last quarter?▼
FMW.STU earnings for the last quarter are -0.26 EUR per share, whereas the estimation was -0.28 EUR resulting in a +6.25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Veru revenue for the last year?▼
Veru revenue for the last year amounts to 0 EUR.
What is Veru net income for the last year?▼
FMW.STU net income for the last year is -20.93M EUR.
Does Veru pay dividends?▼
Yes, FMW.STU dividends are paid quarterly. The last dividend per share was 0.5 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Veru have?▼
As of November 7, 2026, the company has 20 employees.
In which sector is Veru located?▼
Veru operates in the Health & Wellness sector.
When did Veru complete a stock split?▼
The last stock split for Veru was on August 11, 2025 with a ratio of 1:10.
Where is Veru headquartered?▼
Veru is headquartered in MIAMI, United States.